Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences, Inc.

In a report released on September 9, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences, with a price target of $123.00. T...

RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD)

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences today and set a price target of $160.00. Breen covers the Healthcare se...

Gilead Sciences (GILD) Receives a Buy from Bernstein

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vera Therapeutics (VERA) and Gilead Sciences (GILD) ...

Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA) and Gilead Sciences (GILD)

Gilead Sciences stock was down roughly 2% on Friday alongside an FDA update concerning HIV drug Bixlenvo.


	A	B	C	D
1	Symbol	Price	Change	Volume
2	GILD	$150.93	+0.83%	5.28M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GILD	$150.93	+0.8%	5.28M
3
4
5
6

GILD

Get Gilead Sciences, Inc. Data in Excel

Get Gilead Sciences, Inc. Data in Excel